Partnerships, Licensing, Investments and M&A Deals and Trends for October 2016 in Pharmaceuticals

Publisher Name :
Date: 02-Dec-2016
No. of pages: 97
Inquire Before Buying

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for October 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in October 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope


  • Analysis of the market trends for the pharmaceutical industry in the global arena.

  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

  • Analysis of partnership and licensing deals based on clinical stage of development of products.

  • Summary of the pharmaceutical deals globally in the six months.

  • Information on the top deals happened in the pharmaceutical industry.

  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.


Reasons to buy


  • Enhance your decision making capability in a more rapid and time sensitive manner.

  • Find out the major deal performing segments for investments in your industry.

  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

  • Identify companies that are aggressively looking to raise capital in the market

  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

  • Identify growth segments and opportunities in each region within the industry.

  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Partnerships, Licensing, Investments and M&A Deals and Trends for October 2016 in Pharmaceuticals

Table of Contents

1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, October 2016 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, October 2016 14
2.2.1 Samsung Biologics Raises USD2.03 Billion in IPO 14
2.2.2 ConvaTec Raises USD1.8 Billion in IPO 14
2.2.3 China Resources Pharma Raises USD1.8 Million in IPO 15
2.2.4 Allergan Enters into Licensing Agreement with AstraZeneca 16
2.2.5 Astellas Pharma to Acquire Ganymed Pharma 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, October 2016 18
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, October 2016 19

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20
3.1 Pharmaceuticals & Healthcare, Global, M&A, October 2016 20
3.1.1 Top M&A Deals in October 2016 21
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, May 2016 - October 2016 22
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, October 2016 23
3.2.1 Top Equity Offering Deals in October 2016 24
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, May 2016 - October 2016 25
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, October 2016 27
3.3.1 Top PE/VC Deals in October 2016 28
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, October 2016 29
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, October 2016 30
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, May 2016-October 2016 31
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2016-October 2016 32
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2016 33
3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, May 2016 - October 2016 35
3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), October 2016 36
3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, October 2016 37
3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2016 - October 2016 38
3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, May 2016 - October 2016 40
3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), May 2016 - October 2016 41
3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2016 - October 2016 43

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2016 45
4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2016 45
4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2016 47
4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), May 2016 - October 2016 49
4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), May 2016 - October 2016 51
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), May 2016 - October 2016 53
4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), May 2016 - October 2016 55
4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, October 2016 56
4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, October 2016 57
4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, October 2016 58

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 59
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, October 2016 59
5.1.1 Oncology - Deals of the Month 60
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, October 2016 63
5.2.1 Central Nervous System - Deals of the Month 64
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, October 2016 66
5.3.1 Infectious Diseases - Deals of the Month 67
5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, October 2016 69
5.4.1 Cardiovascular - Deal of the Month 70
5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, October 2016 71
5.5.1 Immunology - Deals of the Month 72
5.6 Pharmaceuticals & Healthcare, Global, Respiratory Deals, October 2016 74
5.6.1 Respiratory - Deal of the Month 75
5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, October 2016 76
5.7.1 Metabolic Disorders - Deal of the Month 77

6 Deal Summary by Geography 79
6.1 Pharmaceuticals & Healthcare, North America Deals, October 2016 79
6.1.1 North America - Deals of the Month 80
6.2 Pharmaceuticals & Healthcare, Europe, Deals, October 2016 82
6.2.1 Europe - Deals of the Month 83
6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, October 2016 85
6.3.1 Asia-Pacific - Deals of the Month 86
6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, October 2016 87
6.4.1 Rest of the World - Deals of the Month 88

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 90
7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, May 2016 - October 2016 90
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, May 2016 - October 2016 92

8 Further Information 94
8.1 Methodology 94
8.2 About GlobalData 95
8.3 Disclosure information 95
8.4 Disclaimer 96

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 13
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, October 2016 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), October 2016 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 21
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, October 2016 21
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2016 - October 2016 22
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 24
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, October 2016 24
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 26
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 28
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, October 2016 28
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, May 2016 - October 2016 29
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), October 2016 31
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 32
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2016 - October 2016 32
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 34
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 35
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2016 - October 2016 36
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), October 2016 37
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2016 - October 2016 39
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2016 - October 2016 42
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), May 2016 - October 2016 44
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 46
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), May 2016 - October 2016 48
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 50
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), October 2016 52
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2016 - October 2016 54
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2016 56
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, October 2016 56
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, October 2016 57
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, October 2016 58
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 60
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 64
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 67
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 70
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 72
Table 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 75
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 77
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 80
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 83
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 86
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 88
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 91
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 93

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 12
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), October 2016 18
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), October 2016 19
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 20
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2016 - October 2016 22
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 23
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 25
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 27
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2016 - October 2016 29
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), October 2016 30
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), October 2016 30
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 31
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 33
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 35
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2016 - October 2016 36
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2016 - October 2016 38
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2016 - October 2016 40
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2016 - October 2016 41
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2016 - October 2016 43
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 45
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2016 - October 2016 47
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 49
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2016 - October 2016 51
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, May 2016 - October 2016 53
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), May 2016 - October 2016 53
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), October 2016 55
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 59
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 63
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 66
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 69
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 71
Figure 32: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 74
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 76
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 79
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 82
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 85
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 87
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 90
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2016 - October 2016 92

  • Pharmaceutical Mergers and Acquisitions Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 19-Apr-2019        Price: US 3000 Onwards        Pages: 138
    Pharmaceutical Mergers and Acquisitions Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Pharmaceutical Mergers and Acquisitions industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pharmaceutical Mergers and Acquisitions manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provide......
  • Pharmerging Contract Manufacturings Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 17-Feb-2019        Price: US 3000 Onwards        Pages: 135
    Pharmerging Contract Manufacturings Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Pharmerging Contract Manufacturings industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pharmerging Contract Manufacturings manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-dept......
  • Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2018
    Published: 01-Oct-2018        Price: US 2995 Onwards        Pages: 344
    The Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the ......
  • Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 348
    The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies. The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered i......
  • Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 350
    The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the royalty financing partnering agreements entered into by the worlds leading healthcare companies. The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the royalty financing agreem......
  • Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012 to 2018
    Published: 01-Oct-2018        Price: US 2995 Onwards        Pages: 457
    The Global Co-development Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading healthcare companies. The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered ......
  • Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018
    Published: 01-Oct-2018        Price: US 2995 Onwards        Pages: 2000
    The Global Collaborative R&D Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the collaborative R&D partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the collaborative R&D deals an......
  • Global Academic and Non-Profit Partnering Terms and Agreements 2012-2018: Deal trends, players and financials
    Published: 01-Oct-2018        Price: US 2995 Onwards        Pages: 1000
    Global Academic and Non-Profit Partnering Terms and Agreements 2012 to 2018 report provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals Global Academic and Non-Profit Partnering Terms and Agreements 2012 to 2018 report provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to c......
  • Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018
    Published: 01-Sep-2018        Price: US 2995 Onwards        Pages: 1000
    "Delivery of this report will take 1-3 days after purchase." The Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides details of the latest merger and acquisition (M&A) agreements announced in the pharmaceutical, biotechnology, diagnostic and other lifescience sectors. Fully revised and updated, the report provides details of M&A agreements from 2012 to 2018. The report provides a detailed understan......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs